Profile data is unavailable for this security.
About the company
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.
- Revenue in USD (TTM)4.08bn
- Net income in USD32.48m
- Incorporated1991
- Employees2.52k
- LocationIncyte Corp1801 Augustine Cut-OffWILMINGTON 19803United StatesUSA
- Phone+1 (302) 498-6700
- Fax+1 (302) 636-5454
- Websitehttps://www.incyte.com/
Mergers & acquisitions
| Acquired company | INCY:NSQ since announced | Transaction value |
|---|---|---|
| Escient Pharmaceuticals Inc | 35.04% | 750.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | 3.99bn | 463.16m | 7.21bn | 2.80k | 16.79 | 1.73 | 6.46 | 1.81 | 7.10 | 7.10 | 60.27 | 69.01 | 0.3404 | 0.7371 | 5.91 | 1,425,969.00 | 3.97 | 1.48 | 4.46 | 1.62 | 89.37 | 88.79 | 11.65 | 4.26 | 3.74 | 2.82 | 0.5944 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Roivant Sciences Ltd | 78.54m | 4.76bn | 8.36bn | 845.00 | 2.05 | 1.64 | 1.80 | 106.50 | 5.60 | 5.66 | 0.1007 | 7.03 | 0.019 | -- | 2.91 | 92,940.83 | 111.75 | -- | 139.09 | -- | 89.14 | -- | 5,884.92 | -- | -- | -- | 0.00 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
| Intra-Cellular Therapies Inc | 613.73m | -86.37m | 9.08bn | 610.00 | -- | 7.93 | -- | 14.79 | -0.8595 | -0.8595 | 6.10 | 10.80 | 0.6011 | 1.42 | 4.94 | 1,006,112.00 | -8.46 | -38.27 | -9.74 | -42.77 | 92.30 | -- | -14.07 | -128.42 | 7.51 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Catalent Inc | 4.42bn | -413.00m | 10.71bn | 16.90k | -- | 3.01 | 139.08 | 2.42 | -2.27 | -2.27 | 24.33 | 19.57 | 0.4482 | 4.92 | 3.27 | 261,656.80 | -4.19 | 0.0124 | -4.80 | 0.014 | 21.82 | 28.93 | -9.34 | 0.0278 | 1.93 | 0.7814 | 0.5821 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
| Biomarin Pharmaceutical Inc | 2.75bn | 322.29m | 11.92bn | 3.40k | 37.63 | 2.20 | 28.26 | 4.33 | 1.66 | 1.66 | 14.02 | 28.41 | 0.4046 | 0.5242 | 4.08 | 809,411.60 | 4.74 | 0.7116 | 5.49 | 0.8079 | 78.95 | 76.30 | 11.71 | 2.05 | 2.62 | -- | 0.099 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Incyte Corp | 4.08bn | 32.48m | 13.69bn | 2.52k | 507.68 | 4.32 | 113.35 | 3.36 | 0.14 | 0.14 | 18.79 | 16.45 | 0.715 | 4.23 | 5.76 | 1,614,842.00 | 0.5698 | 9.07 | 0.7404 | 11.02 | 93.37 | 94.97 | 0.7969 | 13.68 | 1.82 | -- | 0.01 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Royalty Pharma plc | 2.27bn | 1.15bn | 15.45bn | 89.00 | 10.25 | 2.26 | 21.53 | 6.82 | 2.56 | 2.56 | 3.80 | 11.63 | 0.1337 | -- | 72.15 | 25,460,710.00 | 10.11 | 9.57 | 13.30 | 12.42 | -- | -- | 75.64 | 67.80 | -- | -- | 0.4258 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Viatris Inc | 15.05bn | -883.30m | 15.67bn | 38.00k | -- | 0.7918 | 8.21 | 1.04 | -0.7389 | -0.7389 | 12.54 | 16.58 | 0.3219 | 2.23 | 4.94 | 396,013.20 | -1.89 | 0.0887 | -2.23 | 0.1061 | 42.49 | 40.29 | -5.87 | 0.2891 | 0.9615 | 2.37 | 0.443 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2024 | 30.74m | 15.96% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 19.66m | 10.21% |
| Dodge & Coxas of 30 Sep 2024 | 15.28m | 7.93% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 12.23m | 6.35% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 10.55m | 5.48% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 4.50m | 2.34% |
| Geode Capital Management LLCas of 30 Sep 2024 | 3.94m | 2.04% |
| Invesco Capital Management LLCas of 30 Sep 2024 | 3.25m | 1.69% |
| LSV Asset Managementas of 30 Sep 2024 | 2.92m | 1.52% |
| AQR Capital Management LLCas of 30 Sep 2024 | 2.70m | 1.40% |
